Mutant IDH1 inhibits PI3K/Akt signaling in human glioma
Cancer, 04/29/2014 Clinical Article
Birner P, et al. – The aim of this study was to investigate a hypothetical relation between IDH1 and PI3K signaling. This study provides patient tumor and in vitro evidence suggesting that mutant IDH1 inhibits PI3K/Akt signaling.
The presence of mutant IDH1 and markers for active PI3K/Akt signaling, present as phosphorylated Akt and podoplanin (PDPN), were investigated in a discovery cohort of 354 patients with glioma.
In vitro experiments were used to confirm functional links.
This study shows an inverse correlation between mutant IDH1 and markers for active PI3K/Akt signaling.
In support of a functional link between these molecules, in vitro expression of mutant IDH1 inhibited Akt phosphorylation in a 2-hydroxyglutarate–dependent manner.
Juxtapid over time will lose the battle. Mr. Beer has decided not to disclose data on juxta just like GENZ is not going to disclose data. If juxta was the sure winner he would go for the kill and let everyone know how superior it is. Also, as time goes on the MTP inhibitor will be exposed as being more dangerous. In their study of only 23 patients, 3 had an elevation of their liver enzymes of 11 times or more. They were allowed to be kept in the study after a drug hiatus and the liver enzymes went back down. If someone drops the ball and a patient continues to take the med they will see liver failure. Mipo shows reversal of liver enzymes to below baseline after seven months of use. I would take ISIS pipeline over the AEGR's two drug, unvaried medication....both drugs are in the same category...another trick by Mr. Beer to buy a potential competitor. Look forward over the next two years to see how juxta really does. t
Read what you said......I only said that she died once, she's wasn't a cat with nine lives. ZAP 3 coming soon. t
Sure you did, you don't really know anything about ISIS. You will know soon, and we will see you BS your way out of the AEGR position. t
You're playing the you are superior card when you post "Yawn 3 too"?! What will you do if there are no profits for another 3 quarters.......double down I suppose. Good luck, don't luck for the FDA to lay off when Mr. Beer had two separate warnings, and he probably violated FDA rules fifty times.....he only got caught twice. Kind of like speeding in your car. t
I have to ask you a question if you really know as much about ISIS as you say. What are the initials of the head of toxicology there? t
So good arguments, but sometimes a stock split....and lately that has been the case, that they are harbingers of good news. SRPT had one, as did several biotechs that moved up sharply shortly after they did. This could be a new trend for biotechs that do have some muscle behind their pipeline. The sooner they get to five the more easily the stock can be obtained by mutual funds, and it becomes marginable then as well. Don't get me wrong, I don't want one, but having one isn't the death of the stock and may bring on quite of bit of wealth shortly thereafter. t
Hey KG, I like all of you selections with about a three year horizon with the exception of CTSO which I don't know about. Will check it out however. Have our annual cookout a HL South on June 28th. Check with G about it and would love to see you their. t
The amount of expenses are going up in order to build infra-structure. They are also getting squeezed from Sanofi/GENZ and Mr. Beer was able to dodge the piper for one more quarter. As time goes on it will be discovered that the fatty infiltration of the liver, the fatty infiltration of the small intestine, the lower HDL, and the increased amount of oxidized LDL will show this to be an inferior drug. The average dosage being given to patients is between 5 and 10mg at a cost of $235K minimum. All the while you have increased risk for fat soluble vitamin deficiencies, malabsorption syndrome, increased inflammatory modulators.......esp. due to that fatty infiltration of the small intestine, the draconian diet, and the diarrhea. Push the dose and you'll see more diarrhea. Then comes some competition from the PCSK9 inhibitors as someone else noted. If this drug fails someone can not say that they have numerous shots on goal. The stock is worth maybe twice its initial offering price. ZAP3 to come. t
Halt-the-infantile has resorted to smutty name calling and the stock will hit new lows today. Good he is on the ground rolling around so he doesn't witness the loss of his money........no wait he sold out a long time ago.......like ya. Where has Yugo gone?? Or is halt-the-arrogant and Yugo one and the same? t
This may be the most important part of the Mr. Beer message not being able to be met:
Given weak first quarter performance, Aegerion will need to kick Juxtapid sales growth into high gear just to meet its new, lowered guidance. Where that growth will come from wasn't made clear during Aegerion's conference call Tuesday night
Blaming lower sales in the US on the weather??? This isn't retail, if someone is on a $295K drug they will find a way to get to the drug store, or have someone pick it up for them. One more quarter like this and Mr. Beer will be fully exposed. He now isn't going to give any script information. Why is that?? Two fold, one is that they are getting their butts kicked as people find out that juxta isn't all it was cracked up to be, and Sanofi/GENZ really putting it to him. t
Another thing to remember thanks Mr. Beer's movie star aspirations is that the FDA will really be watching him even more closely as he becomes a desperato to see if he is going to create even more violations. And then you have the pediatric studies that he is trying to push through, and we haven't even seen the FDA's penalties for his mistakes. t
Instead of saying thank you for pointing out the fact that maybe I might not have all of the facts you continued to denigrate both A1, myself and others. You remind me a lot of Neidimeir on the movie Animal House and your horse just got hit by a golf ball.........enjoy the ride, and I don't have a pledge pin Neidimeir. t
The company is moving methodically ahead. I think they have potential from their three drugs, but also their pipeline, and their delivery system that could take a lot of old generic CA drugs and turn them into new high class winners. There could be a win-win-win situation. The patient would get a better chance at getting cured or better, the insurance carrier could actually save money in not having to pay for so many side-effects and adverse reactions in treatment for them, and RNN could really flourish. I think it will happen. t
Look for my success and ISIS to right back up. Their satalitte company had good news today in a leer reviewed journal for their eye drops:
Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: The I-CAN study
Ophthalmology, 05/12/2014 Clinical Article
Cursiefen C, et al. – The authors aimed to confirm the results of phase II study, in this multicenter, double–masked, randomized, placebo–controlled phase III study and investigated a potential clinical benefit on visual acuity (VA), quality of life (QoL), and need for transplantation. Results showed that aganirsen eye drops significantly inhibited corneal neovascularization in patients with keratitis and the need for transplantation was significantly reduced in patients with viral keratitis and central neovascularization. Thus, topical application of aganirsen was safe and well tolerated.
I know VICL is worth only about a buck and some change going toward BK. But you don't know how good it makes me feel to.know that there is a medication at there, thanks to them, that would allow me to treat my dog should he get melanoma of the mouth.......just like having an insurance policy. t
You are getting me mixed up with halt-the-ranger as I've never played the insider info card. I doubt the ranger will arrest you as you are one of the good guys on his side. This company is not JAZZ, nor is it GILD, and in fact I don't believe it is any of those that you've listed. Time will tell. t